Recursion Pharmaceuticals, Inc.

NASDAQ:RXRX

6.64 (USD) • At close November 4, 2024
Bedrijfsnaam Recursion Pharmaceuticals, Inc.
Symbool RXRX
Munteenheid USD
Prijs 6.64
Beurswaarde 1,887,028,240
Dividendpercentage 0%
52-weken bereik 5.035 - 15.74
Industrie Biotechnology
Sector Healthcare
CEO Dr. Christopher C. Gibson Ph.D.
Website https://www.recursion.com

An error occurred while fetching data.

Over Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment

Vergelijkbare Aandelen

Simulations Plus, Inc. logo

Simulations Plus, Inc.

SLP

27.49 USD

SNDL Inc. logo

SNDL Inc.

SNDL

2.16 USD

Ventyx Biosciences, Inc. logo

Ventyx Biosciences, Inc.

VTYX

2.15 USD

BridgeBio Pharma, Inc. logo

BridgeBio Pharma, Inc.

BBIO

25.2 USD

Varex Imaging Corporation logo

Varex Imaging Corporation

VREX

13.25 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)